Century Therapeutics shares surge 12.75% intraday after Zacks upgrades to Strong Buy, citing improved earnings outlook.

Century Therapeutics surged 12.75% intraday following an upgrade to a Zacks Rank #1 (Strong Buy) rating, reflecting renewed optimism about its earnings potential. The move aligns with the firm’s recent strategic focus, as analysts cited improved outlooks for its therapeutic pipeline and financial performance. While other news, such as mixed earnings updates and leadership changes, had occurred earlier in the year, the immediate catalyst appears to be the analyst upgrade, which likely spurred investor confidence and buying activity during the trading session.